Chroma Therapeutics Ltd.

Chroma Therapeutics Ltd.

Chroma Therapeutics Ltd.

Date Founded



93 Innovation Drive,Milton Park,Abingdon, Oxfordshire OX14 4RZ

Type of Company



Holding Companies

Company Description

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

Contact Data
Trying to get in touch with decision makers at Chroma Therapeutics Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Medical Officer

Pre-Clinical Development Director

Board of Directors

Former Non-Executive Chairman & Chief Executive Officer at Proximagen Group Plc

Chief Executive Officer at eTheRNA immunotherapies NV

Partner at Essex Woodlands Management, Inc.

Paths to Chroma Therapeutics Ltd.
Potential Connections via
Relationship Science
Chroma Therapeutics Ltd.
Recent Transactions
Details Hidden

Aglaia BioMedical Ventures BV, Novo Seeds, Sixth Element Capital LLP, Macrophage Pharma Ltd. purchase Chroma Therapeutics Ltd. /Esterase Sensitive Motif from Chroma Therapeutics Ltd.

Details Hidden

Cancer Research Technology (CRT), Cancer Research UK's commercial arm, and the European Investment Fund (EIF) launched the £50M CPF in 2012 to bridge the UK funding gap between cancer drug discovery and early drug development. Sixth Element Capital was appointed to manage the fund. new fund is the fruit of discussions we've had with the European Investment Fund (EIF), which has a remit to invest in projects to stimulate growth and investment across the European Union.We've agreed that CRT will commit £25 million, while the EIF will match this, doubling the Fund's firepower.As a result, the CRT Pioneer Fund will be able to fund up to £50 million's worth of drug discovery research projects, and will commit to fund them all the way up to entry into phase II trials.At least two-thirds of the fund will be used to develop the most exciting scientific discoveries made by Cancer Research UK scientists. And crucially, these researchers won't have to set up 'spin out' companies - the funds are to be invested in projects, not organisations.

Details Hidden

Abingworth is an active, long-term manager which invests exclusively in companies in the life sciences and healthcare sectors including biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics, instrumentation. Their geographic focus is primarily on the US, UK and Europe.The firm seeks to invest USD 15-30 million in small-cap early and late-stage venture, growth equity and public biotechnology companies with strong management and novel technology that offers a significant improvement over current approaches.Abingworth takes minority or majority stakes in their investee companies, seeking to build relationships with management to create world-class companies.They typically hold an investment for three to eight years.

Details Hidden

Gilde Healthcare Partners BV operates as a venture capital firm that specializes in management buy-outs and growth capital investments in start-up, seed, growth stage, emerging growth, lower middle market, expansion, early, mid, and late stage companies in the healthcare technology and healthcare services sector. It focuses on Healthcare providers and suppliers of goods and services to healthcare providers, biopharma, pharmaceutical, clinical stage therapeutics companies, diagnostics, medical devices, healthcare services including home healthcare services, medical technology, digital healthcare, life sciences, and supporting technologies. The company was founded by Pieter van der Meer and Edwin W. de Graaf in 1999 and is headquartered in Utrecht, the Netherlands

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Chroma Therapeutics Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Chroma Therapeutics Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Chroma Therapeutics Ltd..